{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:50:54Z","timestamp":1792698654977,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140022110014"],"award-info":[{"award-number":["10140022110014"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Staphylococcus aureus bacteraemia (SAB) is associated with high mortality and frequent complications, including acute kidney injury (AKI). Although flucloxacillin has been associated with higher AKI rates than cefazolin, the clinical characteristics of AKI, including severity, timing, recovery and the potential influence of dosing, remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multicentre cohort study across three hospitals in the Netherlands, including adults with SAB treated with cefazolin or flucloxacillin. AKI incidence and severity were compared using adjusted regression analyses. Time-to-event and cumulative incidence analyses were used to evaluate AKI timing and renal recovery. Among flucloxacillin-treated patients, the association between initial dose and AKI was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1408 patients, 483 (34.3%) developed AKI. Most AKI episodes occurred early after index blood culture (median 1.3\u2005days), and recovery within 30\u2005days decreased with increasing AKI severity (81.7% in Stage 1 versus 50.5% in Stage 3). AKI occurred more frequently among patients treated with flucloxacillin than cefazolin (466\/1324 [35.2%] versus 17\/84 [20.2%], P\u200a=\u200a0.004). After multivariable adjustment, flucloxacillin remained associated with higher AKI risk (adjusted OR 2.37, 95% CI 1.30\u20134.55). Among patients with AKI, severity distribution did not differ between treatments (P\u200a=\u200a0.599). Initial flucloxacillin dose was not associated with AKI occurrence, timing or severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Flucloxacillin was associated with increased AKI risk compared with cefazolin, with most AKI episodes occurring early after index blood culture and recovery decreasing with increasing AKI severity. Lower flucloxacillin doses were not associated with reduced AKI risk, suggesting that dose reduction alone may not mitigate flucloxacillin-associated nephrotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag304","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:47:47Z","timestamp":1787140067000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute kidney injury in\n                    <i>Staphylococcus aureus<\/i>\n                    bacteraemia: a multicentre cohort study of incidence, timing, recovery and associations with antibiotic treatment"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-0549","authenticated-orcid":false,"given":"F S","family":"Sinkeler","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I J E","family":"Kouijzer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Radboudumc Community for Infectious Diseases, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-9892","authenticated-orcid":false,"given":"N G L","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-0125","authenticated-orcid":false,"given":"J","family":"ten Oever","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Radboudumc Community for Infectious Diseases, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Leegwater","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Gisolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rijnstate Hospital , Arnhem ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Reuling","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z M","family":"Spoel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M P M","family":"Hensgens","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]},{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"R J","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2026090203432663000_dkag304-B1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026090203432663000_dkag304-B2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40261-022-01204-z","article-title":"Risk factors for nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteraemia: a post hoc analysis of the CAMERA2 trial","volume":"43","author":"Legg","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2026090203432663000_dkag304-B3","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.cmi.2024.06.017","article-title":"Acute kidney injury in Staphylococcus aureus bacteraemia: a recurrent events analysis","volume":"30","author":"Buis","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026090203432663000_dkag304-B4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10096-021-04391-3","article-title":"Acute kidney injury in Staphylococcus aureus bacteremia","volume":"41","author":"Westgeest","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026090203432663000_dkag304-B5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41581-023-00683-3","article-title":"Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup","volume":"19","author":"Zarbock","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2026090203432663000_dkag304-B6","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.2215\/CJN.07630717","article-title":"Drug-induced acute interstitial nephritis","volume":"12","author":"Moledina","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026090203432663000_dkag304-B7","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cmi.2025.04.045","article-title":"Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis","volume":"31","author":"Prosty","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026090203432663000_dkag304-B8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","article-title":"The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"6","author":"Flynt","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2026090203432663000_dkag304-B9","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1056\/NEJMoa2506905","article-title":"Cefazolin for methicillin-susceptible Staphylococcus aureus bacteremia","volume":"394","author":"Lee","year":"2026","journal-title":"N Engl J Med"},{"key":"2026090203432663000_dkag304-B10","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/S0140-6736(25)01624-1","article-title":"Cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial","volume":"406","author":"Burdet","year":"2025","journal-title":"Lancet"},{"key":"2026090203432663000_dkag304-B11","volume-title":"Nephrotoxic Medications. StatPearls [Internet]","author":"Patel","year":"2023"},{"key":"2026090203432663000_dkag304-B12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2008.06.017","article-title":"Establishing age\/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods","volume":"396","author":"Pottel","year":"2008","journal-title":"Clin Chim Acta"},{"key":"2026090203432663000_dkag304-B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/kisup.2011.32","article-title":"Section 2: AKI Definition","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026090203432663000_dkag304-B14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026090203432663000_dkag304-B15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/nep.14246","article-title":"Avoiding misclassification of acute kidney injury: timing is everything","volume":"29","author":"Legg","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"2026090203432663000_dkag304-B16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2215\/CJN.10821011","article-title":"Estimating baseline kidney function in hospitalized patients with impaired kidney function","volume":"7","author":"Siew","year":"2012","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag304\/70910997\/dkag304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/10\/dkag304\/70910997\/dkag304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:43:35Z","timestamp":1788335015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag304\/8779673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag304","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"dkag304"}}